Btomorrow Ventures

Btomorrow Ventures, headquartered in London, is the corporate venture arm of British American Tobacco. The fund operates with a thesis centered on consumer wellness, functional biologies, and proactive digital health, reflecting the strategic interest of its parent in moving toward harm reduction and consumer health categories beyond traditional tobacco. For founders working at the intersection of consumer wellness and AI-enabled health, Btomorrow is a meaningful but specific fit.

The relevant focus areas include digital wellness platforms, biometric tracking, sleep and stress management, oral and respiratory health, functional nutrition, and consumer-facing products that combine biological insights with software-driven personalization. AI is treated as a baseline expectation in modern consumer health, particularly for personalization, behavior change, and longitudinal tracking. Pure clinical software, hospital-facing tools, biotech, and devices are not within the mandate.

Check sizes range from $1M to $5M at entry, typically at seed and Series A. The fund participates as a co-investor in priced rounds and is comfortable taking a strategic minority position rather than necessarily leading. Geography is global, with active deal flow in the United Kingdom, Europe, the United States, and Israel. The strategic value is meaningful: BAT has manufacturing, distribution, and retail capabilities relevant to consumer health, and Btomorrow can selectively connect portfolio companies into those resources where appropriate.

The team includes investment professionals with backgrounds in corporate venture, consumer products, and consumer technology investing. Engagement is structured to balance financial discipline with strategic alignment to BAT’s interests, and portfolio companies should expect a relationship that reflects both elements rather than purely financial board dynamics.

Founders should approach Btomorrow when the company is genuinely a consumer wellness or proactive health business, when AI or data is a substantive engine, and when there is a credible argument for global consumer scale. Introductions through corporate venture networks, consumer health VCs, or accelerator partners working with corporate strategics are the most efficient path. The right time to engage is when the product is in market with early traction and the next round is intended to fund commercial expansion. Founders concerned about a tobacco-related corporate parent should weigh that consideration explicitly before engaging. Companies focused on regulated clinical software, devices, or biotech, or those with cap table sensitivities to corporate strategics, should look elsewhere. For founders building consumer-scale wellness and proactive health businesses comfortable with a strategic corporate investor, Btomorrow offers capital and selective strategic resources that pure financial funds cannot provide.